Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2009 by University of Leipzig
Sponsor:
Collaborators:
Celgene Corporation
Mundipharma Pte Ltd.
Amgen
Information provided by:
University of Leipzig
ClinicalTrials.gov Identifier:
NCT01002703
First received: October 23, 2009
Last updated: August 11, 2011
Last verified: October 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2014
  Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)